ProteoNic licenses tech to Gilead for biologics production

By The Science Advisory Board staff writers

November 5, 2020 -- ProteoNic has licensed its premium 2G UNic technology for boosting therapeutic protein production to Gilead Sciences.

The 2G UNic technology increases transcription and translation rates by combining novel genetic elements and can be easily combined with other protein expression-enhancing technologies to improve performance.

Under the agreement, Gilead will gain nonexclusive commercial rights for application of ProteoNic's technology platform for the development of its proprietary products from mammalian cells.

Financial details of the agreement were not disclosed.If you like this content, please share it with a colleague!


Copyright © 2020 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.